42 results on '"Guttmann-Gruber C"'
Search Results
2. 196 Squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa is associated with dysregulated T cell function
- Author
-
Sharma, A., primary, Nasi, G., additional, Zaafouri, S., additional, Varkhande, S.R., additional, Klicznik, M.M., additional, Umundum, K., additional, Lew, M., additional, Sophianidis, A., additional, Schöftner, L.C., additional, Gerstenberger, A.C., additional, Hofbauer, J.P., additional, Guttmann-Gruber, C., additional, Fortelny, N., additional, Wally, V., additional, Campbell, D.J., additional, and Gratz, I.K., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Metformin shows anti‐neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa‐associated aggressive cutaneous squamous cell carcinoma
- Author
-
Welponer, T., primary, Weber, D. D., additional, Trattner, L., additional, Tockner, B., additional, Aminzadeh‐Gohari, S., additional, Leb‐Reichl, V., additional, Kaufmann, A., additional, Zauner, R., additional, Wimmer, M., additional, Wally, V., additional, Felder, T. K., additional, Strunk, D., additional, Koller, U., additional, Bauer, J. W., additional, Kofler, B., additional, Guttmann‐Gruber, C., additional, and Piñon Hofbauer, J., additional
- Published
- 2023
- Full Text
- View/download PDF
4. 1031 Characterization of staphylococcus aureus isolated from patients with severe recessive dystrophic epidermolysis bullosa
- Author
-
Gruner, S., primary, Trattner, L., additional, Tockner, B., additional, Pjevac, P., additional, Reichelt, J., additional, Tuchscherr de Hauschopp, L., additional, Achleitner, D., additional, Lang, R., additional, Bauer, J., additional, Hofbauer, J. Pinon, additional, and Guttmann-Gruber, C., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Metformin shows anti‐neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa‐associated aggressive cutaneous squamous cell carcinoma.
- Author
-
Welponer, T., Weber, D. D., Trattner, L., Tockner, B., Aminzadeh‐Gohari, S., Leb‐Reichl, V., Kaufmann, A., Zauner, R., Wimmer, M., Wally, V., Felder, T. K., Strunk, D., Koller, U., Bauer, J. W., Kofler, B., Guttmann‐Gruber, C., and Piñon Hofbauer, J.
- Subjects
SQUAMOUS cell carcinoma ,OXIDATIVE phosphorylation ,GLYCOLYSIS ,METFORMIN ,EARLY death ,MERKEL cell carcinoma - Abstract
Background: While most cutaneous squamous cell carcinomas (cSCCs) are treatable, certain high‐risk cSCCs, such as those in recessive dystrophic epidermolysis bullosa (RDEB) patients, are particularly aggressive. Owing to repeated wounding, inflammation and unproductive healing, RDEB patients have a 68% cumulative risk of developing life‐threatening cSCCs by the age of 35, and a 70% risk of death by the age of 45. Despite aggressive treatment, cSCC represents the leading cause of premature mortality in these patients, highlighting an unmet clinical need. Increasing evidence points to a role of altered metabolism in the initiation and maintenance of cSCC, making metabolism a potential therapeutic target. Objectives: We sought to determine the feasibility of targeting tumour cell energetics as a strategy to selectively hinder the growth advantage of aggressive cSCC. Methods: We evaluated the cell energetics profiles of RDEB‐SCC cells by analysing available gene expression data against multiple gene signatures and single‐gene targets linked to metabolic reprogramming. Additionally, we employed real‐time metabolic profiling to measure glycolysis and respiration in these cells. Furthermore, we investigated the anti‐neoplastic properties of the metformin against human and murine high‐risk cSCCs in vitro and in vivo. Results: Gene expression analyses highlighted a divergence in cell energetics profiles between RDEB‐SCC and non‐malignant RDEB keratinocytes, with tumour cells demonstrating enhanced respiration and glycolysis scores. Real‐time metabolic profiling supported these data and additionally highlighted a metabolic plasticity of RDEB‐SCC cells. Against this background, metformin exerted an anti‐neoplastic potential by hampering both respiration and glycolysis, and by inhibiting proliferation in vitro. Metformin treatment in an analogous model of fast‐growing murine cSCC resulted in delayed tumour onset and slower tumour growth, translating to a 29% increase in median overall survival. Conclusions: Our data indicate that metformin exerts anti‐neoplastic properties in aggressive cSCCs that exhibit high‐risk features by interfering with respiration and glycolytic processes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Extracellular matrix distinct signature among dystrophic epidermolysis bullosa variants
- Author
-
Malta, Mariana Jorge Oliveira Cardoso Denis, Osório, H., Guttmann-Gruber, C., Kocher, T., Carvalho, A. F., Cerqueira, Mariana Teixeira, Marques, A. P., and Universidade do Minho
- Subjects
Science & Technology ,Engenharia e Tecnologia::Outras Engenharias e Tecnologias ,COL7A1 ,Extracellular matrix ,Epidermolysis Bullosa - Abstract
Introduction & objectives: Mutations in the COL7A1 gene, which encodes collagen VII protein, the major component of the anchoring fibrils in the dermal-epidermal junction, cause all forms of dystrophic epidermolysis bullosa (DEB). Different clinical variants have been described with both dominant and recessive inheritance. However, information regarding the consequences of different COL7A1 mutations in the cell microenvironment, particularly on extracellular matrix (ECM), is still scarce. Moreover, several studies found the spectrum of biologic and clinical phenotypes of DEB to be wider than initially anticipated. Hence, this work aims to unravel the main differences in ECM composition between DEB patients and healthy individuals, as well as between representative variants of the disease. Materials & methods: Healthy primary fibroblasts and immortalized cell lines of three DEB variants (generalized DDEB, generalized intermediate RDEB and generalized severe RDEB). The cells were seeded at a density of 50x103 cells per cm2 for 14 days with 50μg/mL ascorbic acid, in order to promote maximum ECM deposition. Mass spectrometry-based label-free quantification was used to assess changes in the ECM deposited by the different cell populations. Then a combination of western blot, quantitative real-time PCR and histological methods were used to confirm the proteomic results and investigate the biological pathways linked to the obtained results. Results: Analysis of the extracellular proteome revealed that fibroblasts from each DEB variant have their own proteomic signature. Independently of the DEB variant - and its associated clinical aggressiveness - the different COL7A1 mutations studied impacted dermal ECM organization through the down-regulation of major ECM players such as collagen XII, decorin, biglycan and lysyl oxidase homolog 2. Furthermore, ECM organization-associated proteins were found to be differently expressed between DEB variants. For the phenotypes associated to increased severity of disease, a down-regulation of proteins linked to ECM structure and remodelling, namely collagens I, III and V and matrix metalloproteinases 1 and 2, was observed. Conclusions: Our results corroborate previous studies showing that total loss of collagen VII has an enormous impact on dermal ECM dynamics. Additionally, our results also demonstrated that a partial loss of type VII collagen impacts cell microenvironment, affecting mostly the ECM structural proteins. Overall, our work contributes to the generation of further knowledge on DEB variants molecular features., The authors would like to acknowledge FCT for grant SFRH/BD/137766/2018 (MDM) and contract CEECIND/00695/2017 (MTC), the ERC Consolidator Grant â ECM_INK (ERC-2016-COG-726061) the European Union for The Discoveries Centre for Regenerative and Precision Medicine (H2020-WIDESPREAD-2014-1-739572).
- Published
- 2020
7. Linked in: the extracellular matrix network in tumour dissemination
- Author
-
Leb‐Reichl, V., primary, Guttmann‐Gruber, C., additional, and Piñon Hofbauer, J., additional
- Published
- 2020
- Full Text
- View/download PDF
8. Transforming growth factor‐β messaging: #ContextMatters
- Author
-
Guttmann‐Gruber, C., primary and Piñón Hofbauer, J., additional
- Published
- 2020
- Full Text
- View/download PDF
9. 656 Immune cell profiling of wounds from Epidermolysis bullosa patients
- Author
-
Fuentes, I., primary, Guttmann-Gruber, C., additional, Piñon Hofbauer, J., additional, and South, A., additional
- Published
- 2019
- Full Text
- View/download PDF
10. 741 Reduced microbial diversity is a feature of recessive dystrophic epidermolysis bullosa wounds
- Author
-
Fuentes, I., primary, Guttmann-Gruber, C., additional, Su Ling Tay, A.S., additional, Common, J.E., additional, and South, A.P., additional
- Published
- 2018
- Full Text
- View/download PDF
11. 498 Metformin exerts anti-neoplastic effects against human and murine squamous cell carcinoma
- Author
-
Welponer, T., primary, Trattner, L., additional, Bauer, J.W., additional, Reichelt, J., additional, Kofler, B., additional, Piñón Hofbauer, J., additional, and Guttmann-Gruber, C., additional
- Published
- 2018
- Full Text
- View/download PDF
12. 223 Cancer-type SLCO1B3 as a biomarker for epidermolysis bullosa-associated skin cancer
- Author
-
Guttmann-Gruber, C., primary, Wöss, K., additional, Sun, Y., additional, Furihata, T., additional, Reichelt, J., additional, and Piñón Hofbauer, J., additional
- Published
- 2018
- Full Text
- View/download PDF
13. Transforming growth factor‐β messaging: #ContextMatters.
- Author
-
Guttmann‐Gruber, C. and Piñón Hofbauer, J.
- Abstract
Linked Article: Dayal et al. Br J Dermatol 2021; 184:697–708. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Linked in: the extracellular matrix network in tumour dissemination.
- Author
-
Leb‐Reichl, V., Guttmann‐Gruber, C., and Piñon Hofbauer, J.
- Subjects
- *
EXTRACELLULAR matrix , *TUMORS - Abstract
Linked Article: Caley et al. Br J Dermatol 2021; 184:923–934. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. NETSKINMODELS: A European Network for Skin Engineering and Modeling.
- Author
-
Goreski H, Ilic D, Flacher V, van den Bogaard E, Guttmann-Gruber C, Tanaka RJ, Gülseren G, Marquette C, Fluhr J, Filor V, Sprincean S, and Dubrac S
- Published
- 2024
- Full Text
- View/download PDF
16. Challenges and progress related to gene editing in rare skin diseases.
- Author
-
Piñón Hofbauer J, Guttmann-Gruber C, Wally V, Sharma A, Gratz IK, and Koller U
- Subjects
- Humans, CRISPR-Cas Systems genetics, Quality of Life, Skin, Gene Editing, Skin Diseases genetics, Skin Diseases therapy
- Abstract
Genodermatoses represent a large group of inherited skin disorders encompassing clinically-heterogeneous conditions that manifest in the skin and other organs. Depending on disease variant, associated clinical manifestations and secondary complications can severely impact patients' quality of life and currently available treatments are transient and not curative. Multiple emerging approaches using CRISPR-based technologies offer promising prospects for therapy. Here, we explore current advances and challenges related to gene editing in rare skin diseases, including different strategies tailored to mutation type and structural organization of the affected gene, considerations for in vivo and ex vivo applications, the critical issue of delivery into the skin, and immune aspects of therapy. Against the backdrop of a landmark FDA approval for the first re-dosable gene replacement therapy for a rare genetic skin disorder, gene editing approaches are inching closer to the clinics and the possibility of a local permanent cure for patients affected by these disorders., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. Induced pluripotent stem cell (iPSC) line MLi005-A derived from a patient with dominant dystrophic epidermolysis bullosa (DDEB).
- Author
-
Ropret S, Khurana P, Fabčič T, Cvetkovska J, Trobec A, Jokhadar ŠZ, Ilic D, McGrath JA, Guttmann-Gruber C, and Liovic M
- Subjects
- Humans, Male, Collagen Type VII genetics, Collagen Type VII metabolism, Skin metabolism, Keratinocytes metabolism, Epidermolysis Bullosa Dystrophica genetics, Epidermolysis Bullosa Dystrophica metabolism, Induced Pluripotent Stem Cells metabolism
- Abstract
We have generated MLi005-A, a new induced pluripotent stem cell (iPSC) line derived from skin fibroblasts of a male patient with dominant dystrophic epidermolysis bullosa (DDEB). This iPSC line may be used as a model system for studies on skin integrity, the extracellular matrix and skin barrier function. The characterization of the MLi005-A cell line consisted of molecular karyotyping, next-generation sequencing of the COL7A1 alleles, pluripotency and differentiation potentials testing by immunofluorescence of associated markers in vitro. The MLi-005A line has been also tested for ability to differentiate into fibroblasts and keratinocytes and markers associated with these cell types., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis Bullosa.
- Author
-
Hainzl S, Trattner L, Liemberger B, Bischof J, Kocher T, Ablinger M, Nyström A, Obermayer A, Klausegger A, Guttmann-Gruber C, Wally V, Bauer JW, Hofbauer JP, and Koller U
- Subjects
- Humans, RNA Splicing, Skin, Introns, RNA Precursors, Oligonucleotides, Antisense genetics, Oligonucleotides, Antisense therapeutic use, Collagen Type VII genetics, Epidermolysis Bullosa Dystrophica genetics, Epidermolysis Bullosa Dystrophica therapy
- Abstract
Antisense oligonucleotides (ASOs) represent an emerging therapeutic platform for targeting genetic diseases by influencing various aspects of (pre-)mRNA biology, such as splicing, stability, and translation. In this study, we investigated the potential of modulating the splicing pattern in recessive dystrophic epidermolysis bullosa (RDEB) patient cells carrying a frequent genomic variant (c.425A > G) that disrupts splicing in the COL7A1 gene by using short 2'-O-(2-Methoxyethyl) oligoribo-nucleotides (2'-MOE ASOs). COL7A1 -encoded type VII collagen (C7) forms the anchoring fibrils within the skin that are essential for the attachment of the epidermis to the underlying dermis. As such, gene variants of COL7A1 leading to functionally impaired or absent C7 manifest in the form of extensive blistering and wounding. The severity of the disease pattern warrants the development of novel therapies for patients. The c.425A > G variant at the COL7A1 exon 3/intron 3 junction lowers the efficiency of splicing at this junction, resulting in non-functional C7 transcripts. However, we found that correct splicing still occurs, albeit at a very low level, highlighting an opportunity for intervention by modulating the splicing reaction. We therefore screened 2'-MOE ASOs that bind along the COL7A1 target region ranging from exon 3 to the intron 3/exon 4 junction for their ability to modulate splicing. We identified ASOs capable of increasing the relative levels of correctly spliced COL7A1 transcripts by RT-PCR, sqRT-PCR, and ddPCR. Furthermore, RDEB-derived skin equivalents treated with one of the most promising ASOs exhibited an increase in full-length C7 expression and its accurate deposition along the basement membrane zone (BMZ).
- Published
- 2024
- Full Text
- View/download PDF
19. MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas.
- Author
-
Illmer J, Zauner R, Piñón Hofbauer J, Wimmer M, Gruner S, Ablinger M, Bischof J, Dorfer S, Hainzl S, Tober V, Bergson S, Sarig O, Samuelov L, Guttmann-Gruber C, Shalom-Feuerstein R, Sprecher E, Koller U, Laimer M, Bauer JW, and Wally V
- Subjects
- Humans, Endothelial Cells pathology, Carcinoma, Squamous Cell etiology, Epidermolysis Bullosa Dystrophica genetics, Epidermolysis Bullosa Dystrophica complications, Epithelial-Mesenchymal Transition genetics, MicroRNAs genetics, Skin Neoplasms pathology
- Abstract
Background: Cutaneous squamous cell carcinoma (SCC) is the leading cause of death in patients with recessive dystrophic epidermolysis bullosa (RDEB). However, the survival time from first diagnosis differs between patients; some tumours spread particularly fast, while others may remain localized for years. As treatment options are limited, there is an urgent need for further insights into the pathomechanisms of RDEB tumours, to foster therapy development and support clinical decision-making., Objectives: To investigate differences in RDEB tumours of diverging aggressiveness at the molecular and phenotypic level, with a particular focus on epithelial-to-mesenchymal (EMT) transition states and thus microRNA-200b (miR-200b) as a regulator., Methods: Primary RDEB-SCC keratinocyte lines were characterized with respect to their EMT state. For this purpose, cell morphology was classified and the expression of EMT markers analysed using immunofluorescence, flow cytometry, semi-quantitative reverse transcriptase polymerase chain reaction and Western blotting. The motility of RDEB-SCC cells was determined and conditioned medium of RDEB-SCC cells was used to treat endothelial cells in an angiogenesis assay. In addition, we mined previously generated microRNA (miRNA) profiling data to identify a candidate with potential therapeutic relevance and performed transient miRNA transfection studies to investigate the candidate's ability to reverse EMT characteristics., Results: We observed high variability in EMT state in the RDEB-SCC cell lines, which correlated with in situ analysis of two available patient biopsies and respective clinical disease course. Furthermore, we identified miR-200b-3p to be downregulated in RDEB-SCCs, and the extent of deregulation significantly correlated with the EMT features of the various tumour lines. miR-200b-3p was reintroduced into RDEB-SCC cell lines with pronounced EMT features, which resulted in a significant increase in epithelial characteristics, including cell morphology, EMT marker expression, migration and angiogenic potential., Conclusions: RDEB-SCCs exist in different EMT states and the level of miR-200b is indicative of how far an RDEB-SCC has gone down the EMT path. Moreover, the reintroduction of miR-200b significantly reduced mesenchymal features., Competing Interests: Conflicts of interest The authors declare no conflicts of interest., (© The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists.)
- Published
- 2023
- Full Text
- View/download PDF
20. Biomarker Discovery in Rare Malignancies: Development of a miRNA Signature for RDEB-cSCC.
- Author
-
Zauner R, Wimmer M, Atzmueller S, Proell J, Niklas N, Ablinger M, Reisenberger M, Lettner T, Illmer J, Dorfer S, Koller U, Guttmann-Gruber C, Hofbauer JP, Bauer JW, and Wally V
- Abstract
Machine learning has been proven to be a powerful tool in the identification of diagnostic tumor biomarkers but is often impeded in rare cancers due to small patient numbers. In patients suffering from recessive dystrophic epidermolysis bullosa (RDEB), early-in-life development of particularly aggressive cutaneous squamous-cell carcinomas (cSCCs) represents a major threat and timely detection is crucial to facilitate prompt tumor excision. As miRNAs have been shown to hold great potential as liquid biopsy markers, we characterized miRNA signatures derived from cultured primary cells specific for the potential detection of tumors in RDEB patients. To address the limitation in RDEB-sample accessibility, we analyzed the similarity of RDEB miRNA profiles with other tumor entities derived from the Cancer Genome Atlas (TCGA) repository. Due to the similarity in miRNA expression with RDEB-SCC, we used HN-SCC data to train a tumor prediction model. Three models with varying complexity using 33, 10 and 3 miRNAs were derived from the elastic net logistic regression model. The predictive performance of all three models was determined on an independent HN-SCC test dataset (AUC-ROC: 100%, 83% and 96%), as well as on cell-based RDEB miRNA-Seq data (AUC-ROC: 100%, 100% and 91%). In addition, the ability of the models to predict tumor samples based on RDEB exosomes (AUC-ROC: 100%, 93% and 100%) demonstrated the potential feasibility in a clinical setting. Our results support the feasibility of this approach to identify a diagnostic miRNA signature, by exploiting publicly available data and will lay the base for an improvement of early RDEB-SCC detection.
- Published
- 2023
- Full Text
- View/download PDF
21. A Novel Fluorescence-Based Screen of Gene Editing Molecules for Junctional Epidermolysis Bullosa.
- Author
-
Zwicklhuber J, Kocher T, Liemberger B, Hainzl S, Bischof J, Strunk D, Raninger AM, Gratz I, Wally V, Guttmann-Gruber C, Hofbauer JP, Bauer JW, and Koller U
- Subjects
- Animals, Humans, Gene Editing, Skin, Mutation, Keratinocytes, Epidermolysis Bullosa, Junctional genetics, Epidermolysis Bullosa genetics
- Abstract
Junctional epidermolysis bullosa (JEB) is a severe blistering skin disease caused by mutations in genes encoding structural proteins essential for skin integrity. In this study, we developed a cell line suitable for gene expression studies of the JEB-associated COL17A1 encoding type XVII collagen (C17), a transmembrane protein involved in connecting basal keratinocytes to the underlying dermis of the skin. Using the CRISPR/Cas9 system of Streptococcus pyogenes we fused the coding sequence of GFP to COL17A1 leading to the constitutive expression of GFP-C17 fusion proteins under the control of the endogenous promoter in human wild-type and JEB keratinocytes. We confirmed the accurate full-length expression and localization of GFP-C17 to the plasma membrane via fluorescence microscopy and Western blot analysis. As expected, the expression of GFP-C17
mut fusion proteins in JEB keratinocytes generated no specific GFP signal. However, the CRISPR/Cas9-mediated repair of a JEB-associated frameshift mutation in GFP- COL17A1mut -expressing JEB cells led to the restoration of GFP-C17, apparent in the full-length expression of the fusion protein, its accurate localization within the plasma membrane of keratinocyte monolayers as well as within the basement membrane zone of 3D-skin equivalents. Thus, this fluorescence-based JEB cell line provides the potential to serve as a platform to screen for personalized gene editing molecules and applications in vitro and in appropriate animal models in vivo.- Published
- 2023
- Full Text
- View/download PDF
22. COL7A1 Editing via RNA Trans -Splicing in RDEB-Derived Skin Equivalents.
- Author
-
Liemberger B, Bischof J, Ablinger M, Hainzl S, Murauer EM, Lackner N, Ebner P, Kocher T, Nyström A, Wally V, Mayr E, Guttmann-Gruber C, Hofbauer JP, Bauer JW, and Koller U
- Subjects
- Humans, Trans-Splicing, Skin metabolism, Keratinocytes metabolism, Collagen Type VII genetics, Mutation, Epidermolysis Bullosa Dystrophica genetics, Epidermolysis Bullosa genetics
- Abstract
Mutations in the COL7A1 gene lead to malfunction, reduction or complete absence of type VII collagen (C7) in the skin's basement membrane zone (BMZ), impairing skin integrity. In epidermolysis bullosa (EB), more than 800 mutations in COL7A1 have been reported, leading to the dystrophic form of EB (DEB), a severe and rare skin blistering disease associated with a high risk of developing an aggressive form of squamous cell carcinoma. Here, we leveraged a previously described 3'-RTMS6m repair molecule to develop a non-viral, non-invasive and efficient RNA therapy to correct mutations within COL7A1 via spliceosome-mediated RNA trans -splicing (SMaRT). RTM-S6m, cloned into a non-viral minicircle-GFP vector, is capable of correcting all mutations occurring between exon 65 and exon 118 of COL7A1 via SMaRT. Transfection of the RTM into recessive dystrophic EB (RDEB) keratinocytes resulted in a trans -splicing efficiency of ~1.5% in keratinocytes and ~0.6% in fibroblasts, as confirmed on mRNA level via next-generation sequencing (NGS). Full-length C7 protein expression was primarily confirmed in vitro via immunofluorescence (IF) staining and Western blot analysis of transfected cells. Additionally, we complexed 3'-RTMS6m with a DDC642 liposomal carrier to deliver the RTM topically onto RDEB skin equivalents and were subsequently able to detect an accumulation of restored C7 within the basement membrane zone (BMZ). In summary, we transiently corrected COL7A1 mutations in vitro in RDEB keratinocytes and skin equivalents derived from RDEB keratinocytes and fibroblasts using a non-viral 3'-RTMS6m repair molecule.
- Published
- 2023
- Full Text
- View/download PDF
23. COL17A1 editing via homology-directed repair in junctional epidermolysis bullosa.
- Author
-
Petković I, Bischof J, Kocher T, March OP, Liemberger B, Hainzl S, Strunk D, Raninger AM, Binder HM, Reichelt J, Guttmann-Gruber C, Wally V, Piñón Hofbauer J, Bauer JW, and Koller U
- Abstract
Background: Epidermolysis bullosa (EB), a severe genetic disorder characterized by blister formation in skin, is caused by mutations in genes encoding dermal-epidermal junction proteins that function to hold the skin layers together. CRISPR/Cas9-induced homology-directed repair (HDR) represents a promising tool for editing causal mutations in COL17A1 in the treatment of junctional epidermolysis bullosa (JEB)., Methods: In this study, we treated primary type XVII collagen (C17)-deficient JEB keratinocytes with either Cas9 nuclease or nickase (Cas9n) ribonucleoproteins (RNP) and a single-stranded oligonucleotide (ssODN) HDR template in order to correct a causal pathogenic frameshift mutation within the COL17A1 gene., Results: As analyzed by next-generation sequencing of RNP-nucleofected keratinocytes, we observed an HDR efficiency of ∼38% when cells were treated with the high-fidelity Cas9 nuclease, a mutation-specific sgRNA, and an ssODN template. The combined induction of end-joining repair and HDR-mediated pathways resulted in a C17 restoration efficiency of up to 60% as assessed by flow cytometry. Furthermore, corrected JEB keratinocytes showed a significantly increased adhesive strength to laminin-332 and an accurate deposition of C17 along the basement membrane zone (BMZ) upon differentiation into skin equivalents., Conclusion: Here we present a gene editing approach capable of reducing end joining-generated repair products while increasing the level of seamless HDR-mediated gene repair outcomes, thereby providing a promising CRISPR/Cas9-based gene editing approach for JEB., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Petković, Bischof, Kocher, March, Liemberger, Hainzl, Strunk, Raninger, Binder, Reichelt, Guttmann-Gruber, Wally, Piñón Hofbauer, Bauer and Koller.)
- Published
- 2022
- Full Text
- View/download PDF
24. Paired nicking-mediated COL17A1 reframing for junctional epidermolysis bullosa.
- Author
-
Bischof J, March OP, Liemberger B, Haas SA, Hainzl S, Petković I, Leb-Reichl V, Illmer J, Korotchenko E, Klausegger A, Hoog A, Binder HM, Garcia M, Duarte B, Strunk D, Larcher F, Reichelt J, Guttmann-Gruber C, Wally V, Hofbauer JP, Bauer JW, Cathomen T, Kocher T, and Koller U
- Subjects
- Deoxyribonuclease I genetics, Homozygote, Humans, Laminin genetics, Mutation, Sequence Deletion, Collagen Type XVII, Autoantigens genetics, Epidermolysis Bullosa metabolism, Epidermolysis Bullosa, Junctional genetics, Epidermolysis Bullosa, Junctional therapy, Non-Fibrillar Collagens genetics
- Abstract
Junctional epidermolysis bullosa (JEB) is a debilitating hereditary skin disorder caused by mutations in genes encoding laminin-332, type XVII collagen (C17), and integrin-α6β4, which maintain stability between the dermis and epidermis. We designed patient-specific Cas9-nuclease- and -nickase-based targeting strategies for reframing a common homozygous deletion in exon 52 of COL17A1 associated with a lack of full-length C17 expression. Subsequent characterization of protein restoration, indel composition, and divergence of DNA and mRNA outcomes after treatment revealed auspicious efficiency, safety, and precision profiles for paired nicking-based COL17A1 editing. Almost 46% of treated primary JEB keratinocytes expressed reframed C17. Reframed COL17A1 transcripts predominantly featured 25- and 37-nt deletions, accounting for >42% of all edits and encoding C17 protein variants that localized accurately to the cell membrane. Furthermore, corrected cells showed accurate shedding of the extracellular 120-kDa C17 domain and improved adhesion capabilities to laminin-332 compared with untreated JEB cells. Three-dimensional (3D) skin equivalents demonstrated accurate and continuous deposition of C17 within the basal membrane zone between epidermis and dermis. Our findings constitute, for the first time, gene-editing-based correction of a COL17A1 mutation and demonstrate the superiority of proximal paired nicking strategies based on Cas9 D10A nickase over wild-type Cas9-based strategies for gene reframing in a clinical context., Competing Interests: Declaration of interests T.C. and S.A.H. have filed a patent application for Abnoba-Seq. T.C. has a sponsored research collaboration with Cellectis and is an advisor to Cimeo Therapeutics and Excision BioTherapeutics. The other authors declare no competing interests., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
25. 5'RNA Trans -Splicing Repair of COL7A1 Mutant Transcripts in Epidermolysis Bullosa.
- Author
-
Mayr E, Ablinger M, Lettner T, Murauer EM, Guttmann-Gruber C, Piñón Hofbauer J, Hainzl S, Kaiser M, Klausegger A, Bauer JW, Koller U, and Wally V
- Subjects
- Humans, RNA Splicing, Trans-Splicing, Collagen Type VII genetics, Epidermolysis Bullosa genetics, RNA metabolism
- Abstract
Mutations within the COL7A1 gene underlie the inherited recessive subtype of the blistering skin disease dystrophic epidermolysis bullosa (RDEB). Although gene replacement approaches for genodermatoses are clinically advanced, their implementation for RDEB is challenging and requires endogenous regulation of transgene expression. Thus, we are using spliceosome-mediated RNA trans -splicing (SMaRT) to repair mutations in COL7A1 at the mRNA level. Here, we demonstrate the capability of a COL7A1 -specific RNA trans -splicing molecule (RTM), initially selected using a fluorescence-based screening procedure, to accurately replace COL7A1 exons 1 to 64 in an endogenous setting. Retroviral RTM transduction into patient-derived, immortalized keratinocytes resulted in an increase in wild-type transcript and protein levels, respectively. Furthermore, we revealed accurate deposition of recovered type VII collagen protein within the basement membrane zone of expanded skin equivalents using immunofluorescence staining. In summary, we showed for the first time the potential of endogenous 5' trans -splicing to correct pathogenic mutations within the COL7A1 gene. Therefore, we consider 5' RNA trans -splicing a suitable tool to beneficially modulate the RDEB-phenotype, thus targeting an urgent need of this patient population.
- Published
- 2022
- Full Text
- View/download PDF
26. Transcriptome-Guided Drug Repurposing for Aggressive SCCs.
- Author
-
Zauner R, Wimmer M, Dorfer S, Ablinger M, Koller U, Piñón Hofbauer J, Guttmann-Gruber C, Bauer JW, and Wally V
- Subjects
- Antineoplastic Agents therapeutic use, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell etiology, Data Mining, Drug Repositioning, Epidermolysis Bullosa Dystrophica genetics, Gene Expression Profiling, Gene Expression Regulation, Neoplastic drug effects, Gene Regulatory Networks drug effects, Humans, RNA-Seq, Skin Neoplasms drug therapy, Skin Neoplasms etiology, Antineoplastic Agents pharmacology, Carcinoma, Squamous Cell genetics, Computational Biology methods, Epidermolysis Bullosa Dystrophica complications, Organ Transplantation adverse effects, Skin Neoplasms genetics
- Abstract
Despite a significant rise in the incidence of cutaneous squamous cell carcinoma (SCC) in recent years, most SCCs are well treatable. However, against the background of pre-existing risk factors such as immunosuppression upon organ transplantation, or conditions such as recessive dystrophic epidermolysis bullosa (RDEB), SCCs arise more frequently and follow a particularly aggressive course. Notably, such SCC types display molecular similarities, despite their differing etiologies. We leveraged the similarities in transcriptomes between tumors from organ transplant recipients and RDEB-patients, augmented with data from more common head and neck (HN)-SCCs, to identify drugs that can be repurposed to treat these SCCs. The in silico approach used is based on the assumption that SCC-derived transcriptome profiles reflect critical tumor pathways that, if reversed towards healthy tissue, will attenuate the malignant phenotype. We determined tumor-specific signatures based on differentially expressed genes, which were then used to mine drug-perturbation data. By leveraging recent efforts in the systematic profiling and cataloguing of thousands of small molecule compounds, we identified drugs including selumetinib that specifically target key molecules within the MEK signaling cascade, representing candidates with the potential to be effective in the treatment of these rare and aggressive SCCs.
- Published
- 2022
- Full Text
- View/download PDF
27. Evaluating a Targeted Cancer Therapy Approach Mediated by RNA trans -Splicing In Vitro and in a Xenograft Model for Epidermolysis Bullosa-Associated Skin Cancer.
- Author
-
Woess K, Sun Y, Morio H, Stierschneider A, Kaufmann A, Hainzl S, Trattner L, Kocher T, Tockner B, Leb-Reichl V, Steiner M, Brachtl G, South AP, Bauer JW, Reichelt J, Furihata T, Wally V, Koller U, Piñón Hofbauer J, and Guttmann-Gruber C
- Subjects
- Animals, Cell Line, Cell Survival drug effects, Cell Survival genetics, Disease Management, Disease Models, Animal, Disease Susceptibility, Epidermolysis Bullosa genetics, Epidermolysis Bullosa Dystrophica genetics, Ganciclovir pharmacology, Gene Expression Regulation drug effects, Genetic Loci, Genetic Therapy adverse effects, Humans, Mice, Skin Neoplasms diagnosis, Skin Neoplasms metabolism, Xenograft Model Antitumor Assays, Epidermolysis Bullosa complications, Epidermolysis Bullosa Dystrophica complications, Genetic Therapy methods, RNA Splicing, Skin Neoplasms etiology, Skin Neoplasms therapy, Trans-Splicing
- Abstract
Conventional anti-cancer therapies based on chemo- and/or radiotherapy represent highly effective means to kill cancer cells but lack tumor specificity and, therefore, result in a wide range of iatrogenic effects. A promising approach to overcome this obstacle is spliceosome-mediated RNA trans -splicing (SMaRT), which can be leveraged to target tumor cells while leaving normal cells unharmed. Notably, a previously established RNA trans -splicing molecule (RTM44) showed efficacy and specificity in exchanging the coding sequence of a cancer target gene (Ct-SLCO1B3) with the suicide gene HSV1-thymidine kinase in a colorectal cancer model, thereby rendering tumor cells sensitive to the prodrug ganciclovir (GCV). In the present work, we expand the application of this approach, using the same RTM44 in aggressive skin cancer arising in the rare genetic skin disease recessive dystrophic epidermolysis bullosa (RDEB). Stable expression of RTM44, but not a splicing-deficient control (NC), in RDEB-SCC cells resulted in expression of the expected fusion product at the mRNA and protein level. Importantly, systemic GCV treatment of mice bearing RTM44-expressing cancer cells resulted in a significant reduction in tumor volume and weight compared with controls. Thus, our results demonstrate the applicability of RTM44-mediated targeting of the cancer gene Ct-SLCO1B3 in a different malignancy.
- Published
- 2022
- Full Text
- View/download PDF
28. Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial.
- Author
-
Guttmann-Gruber C, Piñón Hofbauer J, Tockner B, Reichl V, Klausegger A, Hofbauer P, Wolkersdorfer M, Tham KC, Lim SS, Common JE, Diem A, Ude-Schoder K, Hitzl W, Lagler F, Reichelt J, Bauer JW, Lang R, and Laimer M
- Subjects
- Calcitriol analogs & derivatives, Collagen Type VII, Double-Blind Method, Humans, Ointments, Pain drug therapy, Pain etiology, Pruritus drug therapy, Pruritus etiology, Wound Healing, Epidermolysis Bullosa Dystrophica
- Abstract
Background: Wound management is a critical factor when treating patients with the inherited skin fragility disease dystrophic epidermolysis bullosa (DEB). Due to genetic defects in structural proteins, skin and mucous epithelia are prone to blistering and chronic wounding upon minor trauma. Furthermore, these wounds are commonly associated with excessive pruritus and predispose to the development of life-threatening squamous cell carcinomas, underscoring the unmet need for new therapeutic options to improve wound healing in this patient cohort. Vitamin D3 is acknowledged to play an important role in wound healing by modulating different cellular processes that impact epidermal homeostasis and immune responses. In this study, we evaluate the safety and efficacy of low-dose calcipotriol, a vitamin D3 analogue, in promoting wound healing and reducing itch and pain in patients with DEB., Methods: Eligible DEB patients, aged ≥ 6 years and with a known mutation in the COL7A1 gene, were recruited to a placebo-controlled, randomized, double blind, cross-over phase II monocentric clinical trial. Patients were required to have at least two wounds with a minimum size of 6 cm
2 per wound. The primary objective was to evaluate efficacy of daily topical application of a 0.05 µg/g calcipotriol ointment in reducing wound size within a 4-week treatment regimen. Secondary objectives were to assess safety, as well as the impact of treatment on pruritus, pain, and bacterial wound colonization in these patients., Results: Six patients completed the clinical trial and were included into the final analysis. Topical low-dose calcipotriol treatment led to a significant reduction in wound area at day 14 compared to placebo (88.4% vs. 65.5%, P < 0.05). Patients also reported a significant reduction of pruritus with calcipotriol ointment compared to placebo over the entire course of the treatment as shown by itch scores of 3.16 vs 4.83 (P < 0.05) and 1.83 vs 5.52 (P < 0.0001) at days 14 and 28, respectively. Treatment with low-dose calcipotriol did not affect serum calcium levels and improved the species richness of the wound microbiome, albeit with no statistical significance., Conclusions: Our results show that topical treatment with low-dose calcipotriol can accelerate wound closure and significantly reduces itch, and can be considered a safe and readily-available option to improve local wound care in DEB patients. Trial Registration EudraCT: 2016-001,967-35. Registered 28 June 2016, https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001967-35/AT., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
29. Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma.
- Author
-
Leb-Reichl VM, Kienzl M, Kaufmann A, Stoecklinger A, Tockner B, Kitzmueller S, Zaborsky N, Steiner M, Brachtl G, Trattner L, Kreideweiss P, Reinsch C, Panzner S, Greil R, Strunk D, Bauer JW, Gratz IK, Guttmann-Gruber C, and Piñón Hofbauer J
- Subjects
- Animals, Disease Models, Animal, Humans, Mice, CD8-Positive T-Lymphocytes immunology, Carcinoma, Squamous Cell immunology, Immunologic Memory immunology, Measles virus immunology
- Abstract
Viral antigens are among the strongest elicitors of immune responses. A significant proportion of the human population already carries pre-existing immunity against several childhood viruses, which could potentially be leveraged to fight cancer. We sought to provide proof of concept in mouse models that a pre-existing measles virus (MeV) immunity can be redirected to inhibit tumor growth by directly forcing expression of cognate antigens in the tumor. To this end, we designed DNA vaccines against known MeV cytotoxic and helper T epitopes, and administered these intradermally to mice that were subsequently challenged with syngeneic squamous cancer cells engineered to either express the cognate antigens or not. Alternatively, established wild-type tumors in vaccinated animals were treated intratumorally with in vitro transcribed mRNA encoding the cognate epitopes. Vaccination generated MeV cytotoxic T lymphocyte (CTL) immunity in mice as demonstrated by enhanced interferon gamma production, antigen-specific T cell proliferation, and CTL-mediated specific killing of antigen-pulsed target cells. When challenged with syngeneic tumor cells engineered to express the cognate antigens, 77% of MeV-vaccinated mice rejected the tumor versus 21% in control cohorts. Antitumor responses were largely dependent on the presence of CD8+ cells. Significant protection was observed even when only 25% of the tumor bulk expressed cognate antigens. We therefore tested the strategy therapeutically, allowing tumors to develop in vaccinated mice before intratumoral injection with Viromer nanoparticles complexed with mRNA encoding the cognate antigens. Treatment significantly enhanced overall survival compared with controls, including complete tumor regression in 25% of mice. Our results indicate that redirecting pre-existing viral immunity to fight cancer is a viable alternative that could meaningfully complement current cancer immune therapies such as personalized cancer vaccines and checkpoint inhibitor blockade., Competing Interests: Competing interests: Viromer IN VIVO and all Lipocalyx GmbH assets are now part of BioNTech Delivery Technologies GmbH, Halle, Germany. PK, CR, and SP are employees of BioNTech Delivery Technologies GmbH., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
30. Cells from discarded dressings differentiate chronic from acute wounds in patients with Epidermolysis Bullosa.
- Author
-
Fuentes I, Guttmann-Gruber C, Tockner B, Diem A, Klausegger A, Cofré-Araneda G, Figuera O, Hidalgo Y, Morandé P, Palisson F, Rebolledo-Jaramillo B, Yubero MJ, Cho RJ, Rishel HI, Marinkovich MP, Teng JMC, Webster TG, Prisco M, Eraso LH, Piñon Hofbauer J, and South AP
- Subjects
- Acute Disease, Adult, Chronic Disease, Humans, Male, Bandages, Cell Separation, Epidermolysis Bullosa metabolism, Epidermolysis Bullosa pathology, Epidermolysis Bullosa therapy, Granulocytes metabolism, Granulocytes pathology, T-Lymphocytes metabolism, T-Lymphocytes pathology, Wound Healing
- Abstract
Impaired wound healing complicates a wide range of diseases and represents a major cost to healthcare systems. Here we describe the use of discarded wound dressings as a novel, cost effective, accessible, and non-invasive method of isolating viable human cells present at the site of skin wounds. By analyzing 133 discarded wound dressings from 51 patients with the inherited skin-blistering disease epidermolysis bullosa (EB), we show that large numbers of cells, often in excess of 100 million per day, continually infiltrate wound dressings. We show, that the method is able to differentiate chronic from acute wounds, identifying significant increases in granulocytes in chronic wounds, and we show that patients with the junctional form of EB have significantly more cells infiltrating their wounds compared with patients with recessive dystrophic EB. Finally, we identify subsets of granulocytes and T lymphocytes present in all wounds paving the way for single cell profiling of innate and adaptive immune cells with relevance to wound pathologies. In summary, our study delineates findings in EB that have potential relevance for all chronic wounds, and presents a method of cellular isolation that has wide reaching clinical application.
- Published
- 2020
- Full Text
- View/download PDF
31. A cancer stem cell-like phenotype is associated with miR-10b expression in aggressive squamous cell carcinomas.
- Author
-
Wimmer M, Zauner R, Ablinger M, Piñón-Hofbauer J, Guttmann-Gruber C, Reisenberger M, Lettner T, Niklas N, Proell J, Sajinovic M, De Souza P, Hainzl S, Kocher T, Murauer EM, Bauer JW, Strunk D, Reichelt J, Mellick AS, and Wally V
- Subjects
- Cells, Cultured, Gene Expression Regulation, Neoplastic, Humans, Keratinocytes metabolism, Keratinocytes pathology, Neoplasm Invasiveness, Primary Cell Culture, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell pathology, Epidermolysis Bullosa Dystrophica pathology, MicroRNAs physiology, Neoplastic Stem Cells cytology, Neoplastic Stem Cells metabolism, Skin Neoplasms metabolism, Skin Neoplasms pathology
- Abstract
Background: Cutaneous squamous cell carcinomas (cSCC) are the primary cause of premature deaths in patients suffering from the rare skin-fragility disorder recessive dystrophic epidermolysis bullosa (RDEB), which is in marked contrast to the rarely metastasizing nature of these carcinomas in the general population. This remarkable difference is attributed to the frequent development of chronic wounds caused by impaired skin integrity. However, the specific molecular and cellular changes to malignancy, and whether there are common players in different types of aggressive cSCCs, remain relatively undefined., Methods: MiRNA expression profiling was performed across various cell types isolated from skin and cSCCs. Microarray results were confirmed by qPCR and by an optimized in situ hybridization protocol. Functional impact of overexpression or knock-out of a dysregulated miRNA was assessed in migration and 3D-spheroid assays. Sample-matched transcriptome data was generated to support the identification of disease relevant miRNA targets., Results: Several miRNAs were identified as dysregulated in cSCCs compared to control skin. These included the metastasis-linked miR-10b, which was significantly upregulated in primary cell cultures and in archival biopsies. At the functional level, overexpression of miR-10b conferred the stem cell-characteristic of 3D-spheroid formation capacity to keratinocytes. Analysis of miR-10b downstream effects identified a novel putative target of miR-10b, the actin- and tubulin cytoskeleton-associated protein DIAPH2., Conclusion: The discovery that miR-10b mediates an aspect of cancer stemness - that of enhanced tumor cell adhesion, known to facilitate metastatic colonization - provides an important avenue for future development of novel therapies targeting this metastasis-linked miRNA.
- Published
- 2020
- Full Text
- View/download PDF
32. Improved Double-Nicking Strategies for COL7A1-Editing by Homologous Recombination.
- Author
-
Kocher T, Wagner RN, Klausegger A, Guttmann-Gruber C, Hainzl S, Bauer JW, Reichelt J, and Koller U
- Abstract
Current gene-editing approaches for treatment of recessive dystrophic epidermolysis bullosa (RDEB), an inherited, severe form of blistering skin disease, suffer from low efficiencies and safety concerns that complicate implementation in clinical settings. We present a strategy for efficient and precise repair of RDEB-associated mutations in the COL7A1 gene. We compared the efficacy of double-strand breaks (induced by CRISPR/Cas9), single nicks, or double nicks (induced by Cas9n) in mediating repair of a COL7A1 splice-site mutation in exon 3 by homologous recombination (HR). We accomplished remarkably high HR frequencies of 89% with double nicking while at the same time keeping unwanted repair outcomes, such as non-homologous end joining (NHEJ), at a minimum (11%). We also investigated the effects of subtle differences in repair template design on HR rates and found that strategic template-nicking can enhance COL7A1-editing efficiency. In RDEB patient keratinocytes, application of double-nicking led to restoration and subsequent secretion of type VII collagen at high efficiency. Comprehensive analysis of 25 putative off-target sites revealed no off-target activity for double-nicking, while usage of Cas9 resulted in 54% modified alleles at one site. Taken together, our work provides a framework for efficient, precise, and safe repair of COL7A1, which lies at the heart of a future curative therapy of RDEB., (Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
33. Gene Editing-Mediated Disruption of Epidermolytic Ichthyosis-Associated KRT10 Alleles Restores Filament Stability in Keratinocytes.
- Author
-
March OP, Lettner T, Klausegger A, Ablinger M, Kocher T, Hainzl S, Peking P, Lackner N, Rajan N, Hofbauer JP, Guttmann-Gruber C, Bygum A, Koller U, and Reichelt J
- Subjects
- Alleles, Animals, Biopsy, Cell Line, Disease Models, Animal, Exons genetics, Feasibility Studies, Female, Genetic Therapy methods, Humans, Hyperkeratosis, Epidermolytic genetics, Hyperkeratosis, Epidermolytic pathology, Keratin-10 metabolism, Keratinocytes pathology, Keratinocytes transplantation, Male, Mice, Mutation, Primary Cell Culture, Protein Stability, Skin cytology, Transcription Activator-Like Effector Nucleases genetics, Gene Editing methods, Hyperkeratosis, Epidermolytic therapy, Intermediate Filaments metabolism, Keratin-10 genetics, Skin pathology
- Abstract
Epidermolytic ichthyosis is a skin fragility disorder caused by dominant-negative mutations in KRT1 or KRT10. No definitive restorative therapies exist that target these genetic faults. Gene editing can be used to efficiently introduce frameshift mutations to inactivate mutant genes. This can be applied to counter the effect of dominantly inherited diseases such as epidermolytic ichthyosis. In this study, we used transcription activator-like effector nuclease technology, to disrupt disease-causing mutant KRT10 alleles in an ex vivo cellular approach, with the intent of developing a therapy for patients with epidermolytic ichthyosis. A transcription activator-like effector nuclease was designed to specifically target a region of KRT10, upstream of a premature termination codon known to induce a genetic knockout. This proved highly efficient at gene disruption in a patient-derived keratinocyte cell line. In addition, analysis for off-target effects indicated no promiscuous gene editing-mediated disruption. Reversion of the keratin intermediate filament fragility phenotype associated with epidermolytic ichthyosis was observed by the immunofluorescence analysis of correctly gene-edited single-cell clones. This was in concurrence with immunofluorescence and ultrastructure analysis of murine xenograft models. The efficiency of this approach was subsequently confirmed in primary patient keratinocytes. Our data demonstrate the feasibility of an ex vivo gene-editing therapy for more than 95.6% of dominant KRT10 mutations., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
34. Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts.
- Author
-
Atanasova VS, Russell RJ, Webster TG, Cao Q, Agarwal P, Lim YZ, Krishnan S, Fuentes I, Guttmann-Gruber C, McGrath JA, Salas-Alanis JC, Fertala A, and South AP
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cells, Cultured, Child, Child, Preschool, Collagen Type VII genetics, Epidermolysis Bullosa Dystrophica genetics, Female, Fibroblasts pathology, Fibrosis, Gene Knockdown Techniques, Genes, Recessive, Humans, Infant, Infant, Newborn, Male, Middle Aged, Mutation genetics, Phosphorylation, Protein Binding, Signal Transduction, Smad3 Protein metabolism, Thrombospondin 1 genetics, Tumor Microenvironment, Young Adult, Epidermolysis Bullosa Dystrophica metabolism, Extracellular Matrix metabolism, Fibroblasts metabolism, Skin pathology, Thrombospondin 1 metabolism, Transforming Growth Factor beta metabolism
- Abstract
Mutations in the gene encoding collagen VII cause the devastating blistering disease recessive dystrophic epidermolysis bullosa (RDEB). RDEB is characterized by severe skin fragility and nonhealing wounds aggravated by scarring and fibrosis. We previously showed that TSP1 is increased in RDEB fibroblasts. Because transforming growth factor-β (TGF-β) signaling is also increased in RDEB, and TSP1 is known to activate TGF-β, we investigated the role of TSP1 in TGF-β signaling in RDEB patient cells. Knockdown of TSP1 reduced phosphorylation of smad3 (a downstream target of TGF-β signaling) in RDEB primary fibroblasts, whereas overexpression of collagen VII reduced phosphorylation of smad3. Furthermore, inhibition of TSP1 binding to the LAP/TGF-β complex decreased fibrosis in engineered extracellular matrix formed by RDEB fibroblasts, as evaluated by picrosirius red staining and analyses of birefringent collagen fibrillar deposits. We show that collagen VII binds TSP1, which could potentially limit TSP1-LAP association and subsequent TGF-β activation. Our study suggests a previously unreported mechanism for increased TGF-β signaling in the absence of collagen VII in RDEB patient skin. Moreover, these data identify TSP1 as a possible target for reducing fibrosis in the tumor-promoting dermal microenvironment of RDEB patients., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
35. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
- Author
-
Atanasova VS, Pourreyron C, Farshchian M, Lawler M, Brown CA 4th, Watt SA, Wright S, Warkala M, Guttmann-Gruber C, Hofbauer JP, Fuentes I, Prisco M, Rashidghamat E, Has C, Salas-Alanis JC, Palisson F, Hovnanian A, McGrath JA, Mellerio JE, Bauer JW, and South AP
- Subjects
- Antineoplastic Agents pharmacology, Apoptosis, Carcinoma, Squamous Cell diagnosis, Cell Cycle Proteins genetics, Cell Cycle Proteins metabolism, Gene Knockdown Techniques, Genes, Recessive, Glycine pharmacology, Glycine therapeutic use, Humans, Keratinocytes drug effects, Keratinocytes metabolism, Molecular Targeted Therapy, Protein Serine-Threonine Kinases genetics, Protein Serine-Threonine Kinases metabolism, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, RNA, Messenger, RNA, Small Interfering, Skin Neoplasms diagnosis, Sulfones pharmacology, Polo-Like Kinase 1, Antineoplastic Agents therapeutic use, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell etiology, Epidermolysis Bullosa Dystrophica complications, Epidermolysis Bullosa Dystrophica genetics, Glycine analogs & derivatives, Skin Neoplasms drug therapy, Skin Neoplasms etiology, Sulfones therapeutic use
- Abstract
Purpose: Squamous cell carcinoma (SCC) of the skin is the leading cause of death in patients with the severe generalized form of the genetic disease recessive dystrophic epidermolysis bullosa (RDEB). Although emerging data are identifying why patients suffer this fatal complication, therapies for treatment of RDEB SCC are in urgent need. Experimental Design: We previously identified polo-like kinase 1 (PLK1) as a therapeutic target in skin SCC, including RDEB SCC. Here, we undertake a screen of 6 compounds originally designated as PLK1 inhibitors, and detail the efficacy of the lead compound, the multipathway allosteric inhibitor ON-01910, for targeting RDEB SCC in vitro and in vivo ., Results: ON-01910 (or rigosertib) exhibited significant specificity for RDEB SCC: in culture rigosertib induced apoptosis in 10 of 10 RDEB SCC keratinocyte populations while only slowing the growth of normal primary skin cells at doses 2 orders of magnitude higher. Furthermore, rigosertib significantly inhibited the growth of two RDEB SCC in murine xenograft studies with no apparent toxicity. Mechanistically, rigosertib has been shown to inhibit multiple signaling pathways. Comparison of PLK1 siRNA with MEK inhibition, AKT inhibition, and the microtubule-disrupting agent vinblastine in RDEB SCC shows that only PLK1 reduction exhibits a similar sensitivity profile to rigosertib., Conclusions: These data support a "first in RDEB" phase II clinical trial of rigosertib to assess tumor targeting in patients with late stage, metastatic, and/or unresectable SCC., (©2019 American Association for Cancer Research.)
- Published
- 2019
- Full Text
- View/download PDF
36. ÖGDV Preisträger stellen sich vor: Der Wissenschaftspreis der ÖGDV 2018 ging an Dr. Christina Guttmann-Gruber und Dr. Beate Lichtenberger.
- Author
-
Guttmann-Gruber C and Lichtenberger BM
- Published
- 2019
- Full Text
- View/download PDF
37. Reduced Microbial Diversity Is a Feature of Recessive Dystrophic Epidermolysis Bullosa-Involved Skin and Wounds.
- Author
-
Fuentes I, Guttmann-Gruber C, Tay ASL, Piñón Hofbauer J, Denil SLIJ, Reichelt J, Palisson F, Common JEA, and South AP
- Subjects
- Adult, Aged, Austria epidemiology, Biodiversity, Chile epidemiology, Cohort Studies, Epidermolysis Bullosa Dystrophica epidemiology, Epidermolysis Bullosa Dystrophica genetics, Female, Genes, Recessive, Humans, Male, Metagenome, Middle Aged, Skin pathology, Wounds and Injuries pathology, Young Adult, Epidermolysis Bullosa Dystrophica microbiology, Microbiota physiology, Skin microbiology, Staphylococcaceae physiology, Wounds and Injuries microbiology
- Published
- 2018
- Full Text
- View/download PDF
38. Cancer-type organic anion transporting polypeptide 1B3 is a target for cancer suicide gene therapy using RNA trans-splicing technology.
- Author
-
Sun Y, Piñón Hofbauer J, Harada M, Wöss K, Koller U, Morio H, Stierschneider A, Kitamura K, Hashimoto M, Chiba K, Akita H, Anzai N, Reichelt J, Bauer JW, Guttmann-Gruber C, and Furihata T
- Subjects
- Animals, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Colorectal Neoplasms genetics, Colorectal Neoplasms metabolism, Combined Modality Therapy, Ganciclovir pharmacology, Genetic Vectors administration & dosage, HCT116 Cells, HT29 Cells, Humans, Mice, Recombinant Fusion Proteins metabolism, Simplexvirus genetics, Solute Carrier Organic Anion Transporter Family Member 1B3 metabolism, Thymidine Kinase metabolism, Trans-Splicing, Xenograft Model Antitumor Assays, Colorectal Neoplasms therapy, Ganciclovir administration & dosage, Genetic Therapy methods, Solute Carrier Organic Anion Transporter Family Member 1B3 genetics, Spliceosomes genetics, Thymidine Kinase genetics
- Abstract
Cancer-type organic anion transporting polypeptide 1B3 (Ct-OATP1B3) has been identified as a cancer-specific transcript in various solid cancers, including colorectal cancer. Given its excellent cancer-specific expression profile, we hypothesized that Ct-OATP1B3 could represent a promising target for cancer-specific expression of the suicide gene, herpes simplex virus 1 thymidine kinase (HSV-tk), via a spliceosome-mediated RNA trans-splicing (SMaRT) approach. SMaRT technology is used to recombine two RNA molecules to generate a chimeric transcript. In this study, we engineered an RNA trans-splicing molecule carrying a translation-defective HSV-tk sequence (RTM44), which was capable of inducing its own trans-splicing to the desired Ct-OATP1B3 pre-mRNA target. RTM44 expression in LS180 cells resulted in generation of Ct-OATP1B3/HSV-tk fusion mRNA. A functional translation start site contributed by the target pre-mRNA restored HSV-tk protein expression, rendering LS180 cells sensitive to ganciclovir treatment in vitro and in xenografted mice. The observed effects are ascribed to accurate and efficient trans-splicing, as they were absent in cells carrying a splicing-deficient mutant of RTM44. Collectively, our data highlights Ct-OATP1B3 as an ideal target for the HSV-tk SMaRT suicide system, which opens up new translational avenues for Ct-OATP1B3-targeted cancer therapy., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
39. Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes.
- Author
-
Guttmann-Gruber C, Tockner B, Scharler C, Hüttner C, Common JE, Tay ASL, Denil SLIJ, Klausegger A, Trost A, Breitenbach J, Schnitzhofer P, Hofbauer P, Wolkersdorfer M, Diem A, Laimer M, Strunk D, Bauer JW, Reichelt J, Lang R, and Piñón Hofbauer J
- Subjects
- Aged, Antimicrobial Cationic Peptides genetics, Antimicrobial Cationic Peptides metabolism, Calcitriol pharmacology, Cell Line, Cells, Cultured, Epidermolysis Bullosa pathology, Humans, Keratinocytes metabolism, Male, Cathelicidins, Anti-Bacterial Agents pharmacology, Antineoplastic Agents pharmacology, Calcitriol analogs & derivatives, Dermatologic Agents pharmacology, Epidermolysis Bullosa metabolism, Keratinocytes drug effects, Wound Healing
- Abstract
Recessive dystrophic epidermolysis bullosa (RDEB) patients suffer from chronic and repeatedly infected wounds predisposing them to the development of aggressive and life-threatening skin cancer in these areas. Vitamin D3 is an often neglected but critical factor for wound healing. Intact skin possesses the entire enzymatic machinery required to produce active 1-alpha,25-dihydroxyvitamin D3 (calcitriol), underscoring its significance to proper skin function. Injury enhances calcitriol production, inducing the expression of calcitriol target genes including the antimicrobial peptide cathelicidin (hCAP18), an essential component of the innate immune system and an important wound healing factor. We found significantly reduced hCAP18 expression in a subset of RDEB keratinocytes which could be restored by calcipotriol treatment. Reduced scratch closure in RDEB cell monolayers was enhanced up to 2-fold by calcipotriol treatment, and the secretome of calcipotriol-treated cells additionally showed increased antimicrobial activity. Calcipotriol exhibited anti-neoplastic effects, suppressing the clonogenicity and proliferation of RDEB tumor cells. The combined wound healing, anti-microbial, and anti-neoplastic effects indicate that calcipotriol may represent a vital therapeutic option for RDEB patients which we could demonstrate in a single-patient observation study.
- Published
- 2018
- Full Text
- View/download PDF
40. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
- Author
-
Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, Nguyen TN, Coarfa C, Rajapakshe K, Prisco M, Sahu J, Tassone P, Greenawalt EJ, Collisson EA, Wu W, Yao H, Su X, Guttmann-Gruber C, Hofbauer JP, Hashmi R, Fuentes I, Benz SC, Golovato J, Ehli EA, Davis CM, Davies GE, Covington KR, Murrell DF, Salas-Alanis JC, Palisson F, Bruckner AL, Robinson W, Has C, Bruckner-Tuderman L, Titeux M, Jonkman MF, Rashidghamat E, Lwin SM, Mellerio JE, McGrath JA, Bauer JW, Hovnanian A, Tsai KY, and South AP
- Subjects
- DNA Copy Number Variations genetics, DNA Repair genetics, Gene Expression Regulation, Neoplastic, Humans, Mutagenesis genetics, Mutation Rate, Transcriptome genetics, APOBEC Deaminases genetics, Carcinoma, Squamous Cell enzymology, Carcinoma, Squamous Cell genetics, Cytosine Deaminase genetics, Epidermolysis Bullosa Dystrophica enzymology, Epidermolysis Bullosa Dystrophica genetics, Mutation genetics, Skin Neoplasms enzymology, Skin Neoplasms genetics
- Abstract
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare inherited skin and mucous membrane fragility disorder complicated by early-onset, highly malignant cutaneous squamous cell carcinomas (SCCs). The molecular etiology of RDEB SCC, which arises at sites of sustained tissue damage, is unknown. We performed detailed molecular analysis using whole-exome, whole-genome, and RNA sequencing of 27 RDEB SCC tumors, including multiple tumors from the same patient and multiple regions from five individual tumors. We report that driver mutations were shared with spontaneous, ultraviolet (UV) light-induced cutaneous SCC (UV SCC) and head and neck SCC (HNSCC) and did not explain the early presentation or aggressive nature of RDEB SCC. Instead, endogenous mutation processes associated with apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) deaminases dominated RDEB SCC. APOBEC mutation signatures were enhanced throughout RDEB SCC tumor evolution, relative to spontaneous UV SCC and HNSCC mutation profiles. Sixty-seven percent of RDEB SCC driver mutations was found to emerge as a result of APOBEC and other endogenous mutational processes previously associated with age, potentially explaining a >1000-fold increased incidence and the early onset of these SCCs. Human papillomavirus-negative basal and mesenchymal subtypes of HNSCC harbored enhanced APOBEC mutational signatures and transcriptomes similar to those of RDEB SCC, suggesting that APOBEC deaminases drive other subtypes of SCC. Collectively, these data establish specific mutagenic mechanisms associated with chronic tissue damage. Our findings reveal a cause for cancers arising at sites of persistent inflammation and identify potential therapeutic avenues to treat RDEB SCC., (Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
- Published
- 2018
- Full Text
- View/download PDF
41. Extracellular Vesicles as Biomarkers for the Detection of a Tumor Marker Gene in Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
- Author
-
Sun Y, Woess K, Kienzl M, Leb-Reichl VM, Feinle A, Wimmer M, Zauner R, Wally V, Luetz-Meindl U, Mellerio JE, Fuentes I, South AP, Bauer JW, Reichelt J, Furihata T, Guttmann-Gruber C, and Piñón Hofbauer J
- Subjects
- Animals, Biomarkers, Tumor, Humans, Mice, Carcinoma, Squamous Cell etiology, Epidermolysis Bullosa Dystrophica complications, Extracellular Vesicles, Solute Carrier Organic Anion Transporter Family Member 1B3 genetics
- Published
- 2018
- Full Text
- View/download PDF
42. Cancer-Type OATP1B3 mRNA in Extracellular Vesicles as a Promising Candidate for a Serum-Based Colorectal Cancer Biomarker.
- Author
-
Morio H, Sun Y, Harada M, Ide H, Shimozato O, Zhou X, Higashi K, Yuki R, Yamaguchi N, Hofbauer JP, Guttmann-Gruber C, Anzai N, Akita H, Chiba K, and Furihata T
- Subjects
- Animals, Cell Line, Tumor, Colorectal Neoplasms diagnosis, Gene Expression Regulation, Neoplastic, Humans, Male, Mice, Mice, Inbred BALB C, Neoplasm Transplantation, Prognosis, Real-Time Polymerase Chain Reaction, Solute Carrier Organic Anion Transporter Family Member 1B3 biosynthesis, Biomarkers, Tumor genetics, Colorectal Neoplasms blood, Extracellular Vesicles metabolism, RNA, Messenger blood, RNA, Messenger genetics, RNA, Neoplasm blood, RNA, Neoplasm genetics, Solute Carrier Organic Anion Transporter Family Member 1B3 genetics
- Abstract
Cancer-type organic anion transporting polypeptide 1B3 (Ct-OATP1B3) mRNA is a variant isoform of the liver-type OATP1B3. Because Ct-OATP1B3 mRNA shows an excellent cancer-specific expression profile in colorectal cancer (CRC), and that its expression levels are associated with CRC prognosis, it holds the potential to become a useful CRC detection and diagnosis biomarker. While the potential is currently justified only at the tissue level, if existence of Ct-OATP1B3 mRNA in CRC-derived extracellular vesicles (EVs) is validated, the findings could enhance its translational potential as a CRC detection and diagnosis biomarker. Therefore, this study aims at proving that Ct-OATP1B3 mRNA exists in CRC-derived EVs, and can be detected using serum specimens. To examine the possibility of Ct-OATP1B3 mRNA being existed in extracellular milieu, we isolated EVs from the human CRC (HCT116, HT-29, and SW480) cell lines, and prepared their cDNAs. The RT-PCR results showed that Ct-OATP1B3 mRNA was clearly present in EVs derived from the human CRC cell lines. Then, in order to further explore the possibility that Ct-OATP1B3 mRNA in CRC-derived EVs can be detected in serum, we isolated serum EVs derived from human CRC xenograft mice, and then performed RT-PCR. The results showed that Ct-OATP1B3 mRNA could be found in all serum EV and CRC tissue samples of the mice examined. Collectively, our findings, which show that Ct-OATP1B3 mRNA exists in EVs and can be detected in (at least) mouse serum, strengthen the potential use of Ct-OATP1B3 mRNA as a serum-based CRC biomarker.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.